Monteflo 3D ( Montelukast + Fexofenadine + Acebrophylline ) from Edinburgh Pharmaceutical

-

Montelukast + Fexofenadine + Acebrophylline is a combination of three medicines: Montelukast, Fexofenadine and Acebrophylline. Montelukast is a leukotriene antagonist. It works by blocking the action of leukotriene, a chemical messenger. 







This reduces inflammation in the airways and nose, and improves symptoms of allergies. Fexofenadine is an antiallergic which relieves symptoms like runny nose, watery eyes and sneezing. Acebrophylline is a mucolytic which thins and loosens mucus (phlegm), making it easier to cough out.

Courtesy Dr. Sakshi Sharma , Dr. Ashish Ranjan

Get More Information Click On This Website Link - www.edinburghpharma.in and QR Code


Click on Social Accounts - Facebook , LinkedIn & YouTube 




Keywords: #Pharma Franchise in Odisha #Anti-Diabetic PCD# Best PCD Pharma Franchise Company# High Quality Pharma Product# Third Party manufacturing # Top 10 Pharma Franchise# PCD in Uttar Pradesh# Monopoly Phama PCD# Best Pharma Franchise # PCD in Assam# Phama Franchise in Andhra Pradesh, top Pcd Pharma Franchise in India, Medicine Franchise Company List, Pharmaceutical Manufacturing Companies Near Me, Pcd Pharma Franchise Company in Gujarat, Best Pharma Companies, Best Derma PCD Franchise




Comments

Post a Comment

Popular posts from this blog

Fixed-Dose Combination of Dapagliflozin + Sitagliptin + Metformin in Patients with Type 2 Diabetes Poorly Controlled with Metformin: Phase 3, Randomized Comparison with Dual Combinations. Leading Brands Available in India for Dapagliflozin + Sitagliptin + Metformin is SITPIN DM Promoted by Edinburgh Pharmaceuticals.

-
Image
Abstract Introduction:  This study compared efficacy and safety of triple drug fixed-dose combination (FDC) of dapagliflozin (DAPA) + sitagliptin (SITA) + metformin (MET) extended release (ER) with SITA + MET sustained release (SR) and DAPA + MET ER in patients with type 2 diabetes poorly controlled with metformin. Methods:  This phase 3, randomized, open-label, active-controlled study included adult patients with glycated hemoglobin (HbA1c) ≥ 8% (64 mmol/mol) and ≤ 11% (97 mmol/mol), randomized in 1:1:1 ratio to receive either FDC of DAPA + SITA + MET ER (10 mg + 100 mg + 1000 mg) tablets once daily (n = 137) or co-administration of SITA + MET SR (100 mg + 1000 mg) tablets once daily (n = 139) or FDC of DAPA + MET ER (10 mg + 1000 mg) tablets once daily (n = 139). Primary endpoint was mean change in HbA1c from baseline to week 16. Results:  Mean baseline HbA1c was approximately 9% (75 mmol/mol) in each treatment group. At week 16, adjusted mean reduction in HbA1c from ba...
Read more

Meta-analysis of the efficacy and safety of combination of tamsulosin plus dutasteride compared with tamsulosin monotherapy in treating benign prostatic hyperplasia. The leading brand of Tamiflo D range being promoted by Edinburgh Pharmaceuticals in India.

-
Image
  Abstract Background We performed a meta-analysis to confirm the efficacy and safety of the combination of tamsulosin plus dutasteride compared with tamsulosin monotherapy in treating benign prostatic hyperplasia (BPH) during a treatment cycle of at least 1 year. Methods Randomized controlled trials were searched by using MEDLINE, EMBASE, and the Cochrane Controlled Trials Register. Systematic review was carried out using the Preferred Reporting Items for Systematic Reviews and Meta-analyses. The data was evaluated and statistically analyzed by using RevMan version 5.3.0. Results Five studies including 4348 patients were studied. The analysis found that the combination group was significantly greater effect in international prostate symptom score (mean difference [MD], − 1.43; 95% confidence interval [CI], − 2.20 to − 0.66;  P  = 0.0003), prostate volume (MD, − 10.13; 95% CI, − 12.38 to − 7.88;  P  < 0.00001), transitional zone volume (MD, − 3.18; 95% CI, − 3.57 to − ...
Read more